Investigational drug · Phase 2
APHD-002
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Obese With Comorbidities, Obese Patients (BMI ≥ 30 kg/m²).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 16, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "APHD-002"
First trial start
2025
Sep 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "APHD-002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obese With Comorbidities
- Obese Patients (BMI ≥ 30 kg/m²)
Largest trials
Live from ClinicalTrials.gov: studies naming "APHD-002" as an intervention, largest first.
Aphaia Pharma US LLCIndustry
NCT07008456 · 102 participants (planned) · Start Sep 12, 2025 · Primary completion Jul 2026
Drug: APHD-012; APHD-002 and 2 more · For: Obese With Comorbidities; Obese Patients (BMI ≥ 30 kg/m²)
Sites: Tbilisi, Georgia · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Obese With Comorbidities
- APHD-012Phase 21 trial
Aphaia Pharma US LLC · Obese With Comorbidities, Obese Patients (BMI ≥ 30 kg/m²)
- APHP-002Phase 21 trial
Aphaia Pharma US LLC · Obese With Comorbidities, Obese Patients (BMI ≥ 30 kg/m²)
- APHP-012Phase 21 trial
Aphaia Pharma US LLC · Obese With Comorbidities, Obese Patients (BMI ≥ 30 kg/m²)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.